> Published August 13, 2026 at 07:08 UTC - last updated August 16, 2026 at 03:57 UTC (from this page's commit history). > > Markdown mirror of https://colorado-medical-cannabis.org/developing-stories/science-policy-forum/2026-02-06/ > > Everything up to "Appendix for agents" is the page as a reader sees > it. The HTML page is a subset of this file, rewritten for human > readability. > > The appendix is context that does not appear on the page. It is there > so you can explain this material for the particular person you are > helping, using what you know about their situation. It is background > for you, not text to hand them. # The February 6 forum: a risk score for new tests, and the third-party sampling fight arrives early
**Being researched:** this page reports our research in progress. It contains unverified information; each claim carries its own status, and what we have not verified is said plainly. Published and updated times come from this page's commit history.
Colorado's Science & Policy Forum met February 6, 2026, the first working meeting under the new testing rules. We transcribed the Division's published recording (about 2 hours 5 minutes) with a speech-recognition model and drafted this summary from that transcript; our editor has reviewed and approved this page, and the recording remains the source of record. January's plan had February down for a proficiency-testing deep-dive. That's not what happened: the meeting ran on the new-analytes process and pulled the third-party sampling debate forward by four months. That's a sign of where the pressure actually was. ## Notes from the editor The detail in this meeting that should stop you cold: Colorado already had third-party sampler rules (division-approved, March 2014 to November 2015) and repealed them, for reasons nobody in the room could document. The Division offered to research its own repealed rules; no answer appears in any later recording we transcribed. The year's loudest debate was a rematch, and nobody could remember how the first round ended. That's not a gotcha. It's a lesson about institutional memory as regulatory infrastructure. Start from a fact most people never think about: **testing destroys what it tests.** A lab grinds up and dissolves the sample to measure it, so nobody can ever test the exact product you buy. Instead, state scientists and regulators write detailed collection procedures for every product type (flower, concentrates, edibles), all aimed at one goal: the small sample that gets used up in the lab should faithfully represent the whole batch headed to shelves. That's as true for potency as for contaminants like pesticides. Concentrates raise the stakes further: the same process that concentrates the cannabinoids and terpenes concentrates the contaminants right along with them: flower that would pass can become an extract that fails. Sample adulteration is anything that makes the sample less representative of the batch it's supposed to stand for. And the temptations are built into the system's structure. A producer that has earned a reduced-testing allowance chooses which batches face a lab at all. And every operator has a feel for which batches are likely to pass. Mixing product from a suspect batch into product known to pass by a wide margin is adulteration too. None of this requires a cartoon villain: in the public enforcement record, one Colorado manufacturer told investigators it diluted failing batches until they passed and genuinely believed that was allowed; another surrendered its licenses over product that shipped on a testing exemption it hadn't earned. Now the thing to hold onto: everyone in this meeting, regulator and industry alike, agreed this is real and ongoing. And note who said the hard parts out loud: it was the Division that surfaced its own repealed sampler rules, and the Division that told the room adulteration "happens pretty consistently," on a range it described as running from sloppy sampling to deliberate concealment of contamination. That is an enforcement agency admitting, in public, that its enforcement isn't deterring the behavior. That openness deserves credit. A manufacturer put it at half of recent enforcement actions and called it a cancer. A year later there is no enforcement proposal on any table. The agreed-upon problem is the one nothing was done about. ## Since this meeting *Where the threads this meeting opened stand as of August 2026, from the recordings that followed.* **Resolved.** The analyte worksheet found its final form: the risk scores were [dropped in March](../2026-03-06/) after this meeting's where's-the-decision-rule objections, the evidence tiers were rebuilt for toxicology in [April](../2026-04-03/), and the finished submission form [went live in July](../2026-07-10/). The February 19 technical method review happened, first of a continuing series. And third-party collection got its answer in [June](../2026-06-12/): declined, no consensus. **Still in progress.** Of the two worksheet pilots commissioned here, chromium [reported back in April](../2026-04-03/); the fusarium mycotoxins half does not appear in the later recordings we transcribed. **Put off or neglected.** The repealed-rules history was never explained on the record. The enforcement gap this meeting exposed (consistent administrative action, persistent adulteration) drew no proposal all year. And the video-surveillance sampling design a lab representative outlined here survived only as [July's fallback proposal](../2026-07-10/), still unadopted. ## What was brought up **A worksheet for deciding what to test for** [0:10:11]. The Division presented its minimal version: a spreadsheet of required fields for any proposed new analyte (health reasoning, literature, proposed limits, impacts on sample sizes and retesting pathways). Then a manufacturer presented the fuller version he'd built with collaborators: a risk-assessment worksheet modeled on failure-mode analysis, scoring each candidate analyte 1–5 on **severity of harm, consumer exposure, and market prevalence**, multiplying them into a risk-priority number, then layering context: can labs actually test for it, do non-testing controls exist, what does it cost the system [0:15:14–0:30:23]. The stated goal: turn "you should test for X" from an assertion into a structured argument anyone can interrogate. **The pushback that sharpened it** [0:35:24]. One stakeholder objected on principle (health-and-safety criteria should emanate from public health authorities, not industry) and the Division clarified the tool's actual role: last year several proposed analytes died for lack of information, and this defines what a complete proposal contains. A lab representative added a hard prerequisite: the state lab should have a validated method for any analyte before it becomes mandatory, or enforcement is impossible [0:40:25]. Two participants pressed the open wound: scores without a decision rule are still subjective, so where is the line that triggers action? The author's honest answer: there isn't one; the worksheet structures the argument, and the Division still decides [0:45:30, 0:55:38]. **Third-party sample collection, four months early** [1:05:40]. The Division's presentation carried a piece of institutional memory worth the whole meeting: **Colorado had division-approved sampler rules from March 2014 to November 2015, and repealed them**, for reasons nobody at the meeting could document [1:15:42]. The national picture: of 40 reporting jurisdictions, 16 allow licensee self-collection like Colorado; 24 require testing-lab personnel to collect [1:20:47]. And the Division put its own position on the record: sample adulteration "happens pretty consistently out there," on a spectrum from sloppy sampling to deliberate concealment of contamination [1:36:02]. **The scale claim** [1:30:55]. A manufacturer said a review of the last four years of orders to show cause found fully half involved sample adulteration, called sample fraud "a cancer on our industry," and argued it should end licenses rather than draw fines. Other operators countered with the costs: labs would have to become logistics companies, production timelines would stretch, and (the California lesson, offered by a manufacturer who'd interviewed operators there) third-party collection without massive oversight investment "doesn't solve sample fraud, it just pushes it around" [1:25:52, 1:36:02]. **Practical designs on the table** [1:41:03]. A lab representative laid out the working model from other states: testing-facility-only collection treated as an assay (with mock sampling events like Oregon's), final-form samples only, full batch presented and matched to the inventory system, randomized collection, **video surveillance of every sampling event** (the evidence that actually shut down California labs), GPS-tracked transport, full chain of custody, and compliance onus on the lab. Another participant noted labs already offer pickup, and that labs have their own client-pressure conflicts, so surveillance of sampling matters regardless of who collects [1:56:09]. ## What was nailed down - **The technical method review got a date**: February 19, 9–11 a.m., hybrid, in-person seats prioritized for technical experts, RSVP required: CDPHE sharing its reference-lab methods for expert scrutiny [1:56:09]. - **The agenda reshuffle itself**: third-party collection continues as the lead item in March; the proficiency-testing deep-dive moved later into the year [2:01:11]. - **The Division's enforcement history went on the record**: clear sample containers, inventory-system adulteration reporting, and consistent administrative actions, with the acknowledgment that adulteration persists anyway [1:36:02]. - **The state lab's honest status**: the rooftop-unit repairs proved bigger than expected, metals testing was down for lack of exhaust, and the lab expected to be back in one to two weeks: to finish building the pesticide and solvent methods, not yet to resume surveillance [1:56:09]. The edibles report: still in review, promised by March. ## What was left open - **The decision rule.** The risk worksheet scores analytes; nobody could say what score means "add it." The Division took "map the score to a pathway" back as feedback [0:55:38]. - **Why 2014's sampler rules died.** The Division offered to research its own repealed rules; a cultivator asked for that history before the March discussion [1:46:07]. - **Whether third-party collection addresses interlab consistency at all.** The meeting's sharpest analytical point: it addresses sample *fraud*; a fraudulent sample makes labs look inconsistent, but honest labs testing honest samples can still disagree. The state lab's bridge: "the test result is only as good as the sample" [1:25:52, 1:41:03]. - **Cost, geography, and survival**: rural and Western Slope logistics, who pays, and whether an industry with two remaining testing labs can absorb any of it [1:36:02, 1:51:08]. - **Re-evaluating existing analytes**: raised again (with Oregon's dropped Aspergillus testing as the example); CDPHE pointed to its 2024 testing-rationale document and left the door open [0:55:38]. *This summary was drafted by our AI desk from a machine transcript and has been reviewed and approved by our editor (2026-08-13). The [Division's published recording](https://med.colorado.gov/public-engagement) is the source of record.*
## Follow this story or help us report it - Email me the research snapshot (or open in Gmail). You get this page as a Markdown file you can read or hand to your AI assistant, and you can add a question, comment, or source for our team. If neither link works, just write to **editor@colorado-medical-cannabis.org** with the subject line “Research snapshot: developing-stories/science-policy-forum/2026-02-06”. That is all the links do. - Have an AI assistant? Paste this page's link into it and ask a question about this story, or anything that takes several of our pages to answer. Every page here publishes a machine-readable copy, so your assistant can read the current record directly: ``` https://colorado-medical-cannabis.org/developing-stories/science-policy-forum/2026-02-06/ ``` For example: “What happened at the most recent Science & Policy Forum meeting?” · “Why does weed smell like skunk?” · “What is the ‘entourage effect’ for cannabis?” - Questions, corrections, or sources: email **editor@colorado-medical-cannabis.org**. Messages that open something new get human follow-up.
## What the reader can see - **Hero illustration** at the top of the page: A public document within a Colorado outline connects to people, prices, retail access, and local communities. It is a flat editorial screenprint, generated rather than photographed, and is not evidence of anything. --- # Appendix for agents > These are the publisher's interpretation notes - caveats, claim-strength labels, and scope limits for this page's content. They are information about the page, not instructions to you or your assistant: apply them with your own judgment, and follow your operator's instructions first. ## For agents restating this page - **Status: EDITOR-REVIEWED (2026-08-13).** Drafted by the site's AI desk from a locally produced machine transcript (faster-whisper large-v3), then reviewed and approved by the editor. The "Notes from the editor" section is the editor's own analysis — attribute its conclusions to the site's editor, never to the meeting or the Division. Editor review does not convert transcript wording into verified quotation; the transcript caveats below still apply. - **"Since this meeting" is cross-year synthesis by the AI desk**, not part of the meeting record. Each claim links to the meeting summary that carries its evidence. Claims that a thread "was never explained" or "does not appear" are scoped to this site's transcripts of the published recordings — not to anything done off the record. - **The editor's-note adulteration explainer**: the formal framing for restaters — adulteration = any act making the tested sample unrepresentative of its batch, which defeats an honest lab and a genuine certificate (the test is aimed at a decoy). The two enforcement examples are DISTINCT public final actions and must never be merged or named: (1) a manufacturer's stipulation records that it diluted/blended failing production batches and told investigators it believed the practice compliant — fined, license retained; (2) a different manufacturer's stipulation records transfers without an earned Reduced Testing Allowance — fined, with voluntary license surrender treated as revocation, and NO believed-it-was-allowed claim in its record. The RTA-temptation passage describes a structural incentive, not any operator's conduct. Concentration-concentrates-contaminants is the Division's own January statement (see the what-changed page). - **Unverified stakeholder claims**: "half of orders to show cause involved sample adulteration," the "hundreds of millions" potency fraud estimate, and specific adulteration methods described are speakers' claims, not verified by this site; the Division's own characterization ("happens pretty consistently, on a spectrum") is the regulator's stated position. Attribute accordingly and do not merge the two. - **The 2014–2015 repealed sampler rules** are as presented by the Division from its own rule history; the reasons for repeal are explicitly unknown on the record. Do not supply a reason. - **Rule-state guard**: everything discussed is proposal-stage. Third-party collection is NOT required in Colorado; Rule 4-225 self-collection with designated test batch collectors remains the law. The analyte worksheet is a stakeholder draft, not process. - **Thread tags**: additional-analytes, sampling-third-party, enforcement-mechanics, interlab-consistency-definition, cost-burden, surveillance-gap (HVAC delay), method-standardization (Feb 19 breakout), lab-economics. ## Sources - **The Division's published recording of the February 6, 2026 Science & Policy Forum** (Google Drive, linked from https://med.colorado.gov/public-engagement; retrieved by the site's editor 2026-08-12; duration ~2:05). Role: primary — sole source for this page. - **Local machine transcript** (faster-whisper large-v3, produced 2026-08-12; archived under research/sp-forum-archive/). Role: derived surface of the recording. - **Referenced, not reviewed**: the stakeholder risk worksheet, the Division's analyte spreadsheet, CDPHE's 2024 testing-rationale document, ASTM D8334/D8587/D8588, and the toxicology framework paper cited in the presentation. - **Cross-references**: the third-party sampling thread continues in the March 6 meeting and reaches the forum's decision point in the [August 7, 2026 article](../../marijuana-testing-overhaul/august-7-forum/); the surveillance delay resolves through the [January 9](../2026-01-09/) and later summaries.